Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma Recruiting Phase 1 / 2 Trials for Brentuximab vedotin (DB08870)

IndicationStatusPhase
DBCOND0029305 (Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01805037Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTreatment